Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 4
1952 2
1953 2
1954 2
1955 100
1956 309
1957 373
1958 314
1959 236
1960 188
1961 124
1962 169
1963 455
1964 668
1965 402
1966 351
1967 473
1968 475
1969 560
1970 551
1971 697
1972 664
1973 761
1974 763
1975 732
1976 604
1977 577
1978 602
1979 584
1980 594
1981 648
1982 700
1983 717
1984 822
1985 869
1986 776
1987 830
1988 802
1989 904
1990 924
1991 996
1992 1033
1993 930
1994 937
1995 928
1996 931
1997 890
1998 1001
1999 918
2000 981
2001 969
2002 1060
2003 1124
2004 1064
2005 1167
2006 1243
2007 1247
2008 1252
2009 1282
2010 1394
2011 1465
2012 1554
2013 1487
2014 1554
2015 1495
2016 1479
2017 1530
2018 1593
2019 1503
2020 1251
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

53,946 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis.
Krasselt M, Baerwald C. Krasselt M, et al. Drug Des Devel Ther. 2016 Mar 8;10:1047-58. doi: 10.2147/DDDT.S87792. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27022244 Free PMC article. Review.
The introduction of modified-release (MR) prednisone adds a drug with encouraging potential to the armamentarium of the rheumatologist. ...The efficacy and safety of MR prednisone use in rheumatoid arthritis patients are reviewed in this article. ...
The introduction of modified-release (MR) prednisone adds a drug with encouraging potential to the armamentarium of the rheumatologis …
Riesenzellarteriitis: Tocilizumab zusätzlich zu Prednison steigert die Rate länger anhaltender Remissionen.
Steurer J. Steurer J. Praxis (Bern 1994). 2017;106(22):1251-1252. doi: 10.1024/1661-8157/a002823. Praxis (Bern 1994). 2017. PMID: 29088969 Clinical Trial. German. No abstract available.
A study on the removal of prednisone from aqueous solutions by adsorption onto a vegetal activated carbon.
Zanette JC, Veit MT, Gonçalves GC, Palácio SM, Scremin FR, Torquato AS, Vieira MRSA. Zanette JC, et al. Water Sci Technol. 2018 Dec;78(11):2328-2337. doi: 10.2166/wst.2018.515. Water Sci Technol. 2018. PMID: 30699084
This study evaluated the prednisone removal from aqueous solutions using adsorption by an activated carbon of vegetal origin (VAC). A central composite rotatable design (CCRD) and the response surface methodology (RSM) were used to verify the influence of the parameters: p …
This study evaluated the prednisone removal from aqueous solutions using adsorption by an activated carbon of vegetal origin (VAC). A …
[A vulnerable elderly man with prednisone-induced delirium].
Otten RI, Jansen IHM, Zeeman M. Otten RI, et al. Ned Tijdschr Geneeskd. 2019 May 9;163:D3544. Ned Tijdschr Geneeskd. 2019. PMID: 31120224 Dutch.
A vulnerable elderly man with prednisone-induced delirium Background Delirium always has an underlying cause, for example, medication. ...The provoking factor can be slight, for example 15 or 5 mg of prednisone. So be careful when starting prednisone in vulne …
A vulnerable elderly man with prednisone-induced delirium Background Delirium always has an underlying cause, for example, medication …
[Prednisone].
LINDEBOOM GA, VAN DER MEER C. LINDEBOOM GA, et al. Ned Tijdschr Geneeskd. 1956 Nov 24;100(47):3438-47. Ned Tijdschr Geneeskd. 1956. PMID: 13387904 Dutch. No abstract available.
[Cortancyl].
de Charnace B, Gervais C. de Charnace B, et al. Soins. 1982 Aug;(387-388):67-71. Soins. 1982. PMID: 6924410 French. No abstract available.
Corticosteroid pharmacokinetics in liver disease.
Uribe M, Go VL. Uribe M, et al. Clin Pharmacokinet. 1979 May-Jun;4(3):233-40. doi: 10.2165/00003088-197904030-00005. Clin Pharmacokinet. 1979. PMID: 383357 Review.
Among the corticosteroids, prednisone is the most commonly used in the treatment of chronic active liver disease. However, its pharmacokinetics have only recently been investigated. Prednisone is effectively absorbed and converted to its active therapeutic derivativ …
Among the corticosteroids, prednisone is the most commonly used in the treatment of chronic active liver disease. However, its pharma …
Delayed-release prednisone (Rayos).
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2012 Nov 26;54(1404):94. Med Lett Drugs Ther. 2012. PMID: 23183387 No abstract available.
[Hashimoto encephalitis and depression].
Veltman EM, Rhebergen D, van Exel E, Stek ML. Veltman EM, et al. Tijdschr Psychiatr. 2015;57(4):280-3. Tijdschr Psychiatr. 2015. PMID: 25904434 Free article. Dutch.
Hashimoto encephalitis (he) is an auto-immune disease, with 40-50% of patients developing psychopathology. This could require targeted treatment. HE and prednison could both cloud the identification of a concurrent depressive disorder. ...
Hashimoto encephalitis (he) is an auto-immune disease, with 40-50% of patients developing psychopathology. This could require targeted treat …
Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone.
Schalm SW, Summerskill WH, Go VL. Schalm SW, et al. Gastroenterology. 1977 May;72(5 Pt 1):910-3. Gastroenterology. 1977. PMID: 849821
To determine the effect of impaired liver function on conversion of prednisone to prednisolone, and to investigate the relationship of this to responses to treatment with prednisone, we measured serum prednisone and prednisolone by radioimmunoassay after 10 m …
To determine the effect of impaired liver function on conversion of prednisone to prednisolone, and to investigate the relationship o …
53,946 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback